



FINANCIAL TEAR SHEET

CORPORATE PROFILE

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead program, CTX001, aims to treat Sickle cell disease and β -thalassemia using an ex vivo approach. We are also pursuing oncology indications with our allogeneic CAR-T platform and liver, lung, and neuromuscular indications using in vivo approaches. In addition, we have established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases with high unmet need. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. We are headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and select business operations in London, United Kingdom.

PRIMARY IR CONTACT


Chris Brinzey
Westwicke Partners
Phone: 339-970-2843
E-mail:
chris.brinzey@westwicke.com

STOCK PERFORMANCE

CRSP (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$63.76
Change (%)	▼ 0.84 (1.30%)
Volume	1,154,716
52 Week Low	\$13.50
Market Cap	\$3,015,580,649
Rolling EPS	-1.63
PE Ratio	0
Shares Outstanding	46,680,815

Data as of 05/22/18 4:00 p.m. ET



RECENT HEADLINES & EVENTS

May-15-2018 - 8:00 a.m.
CRISPR Therapeutics Announces Presentations
at the ASGCT 21st Annual Meeting

There are currently no events scheduled.

May-08-2018 - 8:00 a.m.
CRISPR Therapeutics Provides Business Update
and Reports First Quarter 2018 Financial Results

May-03-2018 - 4:02 p.m.
CRISPR Therapeutics to Participate in May
Investor Conferences

SEC FILINGS

Filing Date	Form
05/21/18	4
05/17/18	4
05/17/18	4
05/15/18	4

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources